Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TAK-411

Plasma-derived product · developed by TAKEDA PHARMACEUTICAL CO

Phase 2 Most advanced trial
TAK Developer
1 Registered trials

What is TAK-411?

TAK-411 is a hypersialylated immune globulin G, a plasma-derived immunoglobulin preparation. It is being studied in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a neurological disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Hypersialylated Immune Globulin G
Drug type
Plasma-derived product
Therapy area
Neurology
Developer
TAKEDA PHARMACEUTICAL CO (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06798012 Phase 2 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

More from TAKEDA PHARMACEUTICAL CO

Follow TAK, the company behind TAK-411

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.